Literature DB >> 22262035

Trial watch: BTK inhibitor shows positive results in B cell malignancies.

Charlotte Harrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22262035     DOI： 10.1038/nrd3656

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

1.  Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Authors:  Idit Sagiv-Barfi; Holbrook E Kohrt; Laura Burckhardt; Debra K Czerwinski; Ronald Levy
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113

2.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

3.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

4.  Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.

Authors:  Irene Guendel; Sergey Iordanskiy; Gavin C Sampey; Rachel Van Duyne; Valerie Calvert; Emanuel Petricoin; Mohammed Saifuddin; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  J Neurovirol       Date:  2015-02-12       Impact factor: 2.643

5.  The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.

Authors:  Girija Dasmahapatra; Hiral Patel; Paul Dent; Richard I Fisher; Jonathan Friedberg; Steven Grant
Journal:  Br J Haematol       Date:  2013-01-30       Impact factor: 6.998

6.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

7.  Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads.

Authors:  Qiumeng Zhang; Zonglong Hu; Qianqian Shen; Yi Chen; Wei Lu
Journal:  Molecules       Date:  2017-05-12       Impact factor: 4.411

8.  MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

Authors:  Mark Cobbold; Hugo De La Peña; Andrew Norris; Joy M Polefrone; Jie Qian; Ann Michelle English; Kara L Cummings; Sarah Penny; James E Turner; Jennifer Cottine; Jennifer G Abelin; Stacy A Malaker; Angela L Zarling; Hsing-Wen Huang; Oliver Goodyear; Sylvie D Freeman; Jeffrey Shabanowitz; Guy Pratt; Charles Craddock; Michael E Williams; Donald F Hunt; Victor H Engelhard
Journal:  Sci Transl Med       Date:  2013-09-18       Impact factor: 17.956

9.  Novel Bruton's tyrosine kinase inhibitors currently in development.

Authors:  Osmond J D'Cruz; Fatih M Uckun
Journal:  Onco Targets Ther       Date:  2013-03-06       Impact factor: 4.147
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.